Datopotamab Deruxtecan-dlnk

(DA-toh-POH-tuh-mab DEH-rux-TEE-kan)

Datopotamab deruxtecan-dlnk is a type of targeted therapy drug called an antibody–drug conjugate. It consists of a monoclonal antibody linked to a toxic drug called deruxtecan that binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and blocks an enzyme called topoisomerase I. This damages the DNA of the cancer cells and kills them.

US Brand Name(s)

Datroway

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Datopotamab deruxtecan-dlnk is approved to treat:

Breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It is used in adults who have received hormone therapy and chemotherapy for cancer that has spread or cannot be removed by surgery.

Datopotamab deruxtecan-dlnk is also being studied in the treatment of other types of cancer.

More About Datopotamab Deruxtecan-dlnk

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Datopotamab Deruxtecan-dlnk - Check for trials from NCI's list of cancer clinical trials now accepting patients.